Juan Felipe Colmenares Guzmán

A multimodal approach is recommended to optimize perioperative pain control in animals, although opioid use in horses remains limited due to the risks of central nervous system (CNS) stimulation and reduced intestinal motility. A group of 19 healthy, male, mixed-breed horses were divided into two groups and medicated with acepromazine (0.05 mg kg⁻¹) and detomidine (10 µg kg⁻¹), with methadone (0.05 mg kg⁻¹) (ADM) or saline (ADS) administered intravenously (IV). Physiological variables, intestinal motility, gastric distention, and facial pain (EQUUS-FAP) were evaluated one day before (DB), before the surgical procedure (BS), and at 1, 2, 4, 6, and 8 h (T1h–T8h) after administration (ADM-ADS). Results are presented as means with standard deviation or medians with an interquartile range. Analysis of variance, the Mann–Whitney, and Durbin tests were applied (p < 0.05). Intestinal motility was reduced at T1h and T2h, returning to baseline by T6h and T8h in both groups. Ultrasonographic examination revealed reduced motility, with less significant changes in the left ventral colon (LVC), right ventral colon (RVC), and cecum. Gastric dilatation was more pronounced in the ADM group at T1, 4, 6, and 8h. EQUUS-FAP scores were significantly lower in ADM at T2, 4, and 6h. ADM protocol may aid chemical restraint and analgesia without increasing hypomotility.

Morphine has significant clinical and analgesic effects in horses, but its impact on the gastrointestinal tract requires further understanding. This study assessed the analgesic and gastrointestinal effects of morphine in horses undergoing elective orchiectomy in the quadrupedal position. Thirty uncastrated male horses were randomly assigned to three groups: orchiectomy without morphine and sedation protocol (OSM), orchiectomy with morphine and sedation protocol (OM), and administration of morphine alone in the absence of orchiectomy (M). The anesthetic protocol involved acepromazine (0.05 mg/kg IV) and detomidine (10 mcg/kg IV) sedation in groups OSM and OM, with morphine sulfate (0.05 mg/kg IV) given to OM and M, and NaCl to OSM. The team measured clinical parameters, pain, and sedation using the EQUUS-FAP scale, while they monitored bowel motility and gastric dilation through abdominal ultrasound. These assessments were performed on the previous day (m1), 20 min before surgery (m2), and at various time points following the administration of morphine or saline solution: one hour (m3), two hours (m4), four hours (m5), six hours (m6), and eight hours (m7) post-procedure for all three groups. There was no significant difference in pain score between OSM and OM, though OM had better sedation. Ultrasound revealed decreased colon contractions and minor gastric dilation in OSM and OM, normalizing within 6 h. Group M showed reduced motility and significant gastric dilation lasting 8 h. In conclusion, while morphine enhanced sedation without causing greater gastrointestinal dysfunction than OSM, its administration alone resulted in a more pronounced reduction in gastrointestinal motility and an increased risk of gastric dilation.

The present study involved seven horses in a randomized crossover clinical trial to evaluate the effect of lidocaine on horses with induced endotoxemia. Horses received intravenous lidocaine (1.5 mg/kg bolus, followed by 0.05 mg/kg bwt/min) or placebo (0.9% sodium chloride at the same manner) one hour before LPS administration (0.03 μg/kg, IV infusion over 30 min). We monitored clinic and hematologic parameters, abdominal auscultation, ultrasound, and pain over time. No relevant clinical differences existed between treatments regarding peristalsis, abdominal pain, or any other parameters before and after endotoxemia induction. These findings do not support the clinical use of lidocaine to mitigate abdominal pain and intestinal hypomotility promoted by endotoxemia in horses.